earnings
confidence high
sentiment neutral
materiality 0.50
Reneo Q1 net loss $13.0M; STRIDE enrollment 50% done; LC-FAOD data in July 2022
OnKure Therapeutics, Inc.
2022-Q1 EPS reported
-$0.53
- Net loss of $13.0M ($0.53/share) vs $7.2M loss ($3.48/share) in Q1 2021.
- Cash, equivalents and short-term investments of $138.7M as of March 31, 2022.
- R&D expenses rose to $9.3M from $5.5M, driven by STRIDE and FORWARD studies.
- Enrolled 100th patient in STRIDE Phase 2b PMM trial; target enrollment 200.
- Phase 1b and FORWARD natural history study results in LC-FAOD expected July 2022.